Baseline and dynamic changes in haemoglobin levels predict treatment response and prognosis in metastatic renal cell carcinoma – a multicentre retrospective study
Yu-Hsuen Yang,Sonam Ansel,Francesca Jackson-Spence,Kathrine Rallis,Paul Brian,Julia Choy,Christopher Sng,Philip Adeniran,Jubel Amin,Sarah Galope,Naomi Anderson,Axel Bex,Thomas Powles,Balaji Venugopal,Bernadett Szabados,Aafke Meerveld-Engink
DOI: https://doi.org/10.1016/j.clgc.2023.02.001
IF: 3.121
2023-02-11
Clinical Genitourinary Cancer
Abstract:INTRODUCTION Clinical markers of response in metastatic renal cell carcinoma (mRCC) are lacking. Low haemoglobin (Hb) is associated with poor outcomes in the IMDC risk score. This study evaluates the role of Hb as a marker of treatment outcomes in mRCC. PATIENTS AND METHODS This multicentre retrospective study evaluated 276 patients with mRCC treated with frontline immune checkpoint inhibitor (ICI) therapy, ICI and VEGF inhibitor (VEGFI) combinations (ICI/VEGFI), or VEGFI monotherapy between 2014 to 2021. Hb levels at baseline, week 6 and 12 and at disease progression or death were recorded. Patients were categorised as responders (CR+PR) or non-responders (SD+PD) using cross-sectional imaging at week 12. The association between baseline and dynamic changes in Hb and oncological outcomes was assessed. RESULTS 37%, 40% and 22% of patients received ICIs, ICI/VEGFI and VEGFI respectively. Baseline clinicopathological characteristics were similar across these groups with a median follow-up of 9.7 months. In patients receiving ICIs, there was a significant increase in Hb amongst responders from baseline to week 12 (p = 0.02). Amongst patients receiving ICI/VEGFI, there was an increase in Hb from baseline to week 12 for both responders and non-responders which was greater in responders (p < 0.001). In patients receiving VEGFI monotherapy, responders had a higher Hb at baseline (p = 0.01), week 6 (p = 0.04) and week 12 (p = 0.003). There was a decrease in Hb amongst both responders and non-responders at week 12, although this was only significant amongst non-responders (p = 0.03). An increase in Hb was a significant independent predictor of progression-free survival amongst patients receiving ICIs (HR 0.40, 95%CI 0.19 – 0.83, p = 0.009) but not in those receiving ICI/VEGFI or VEGFI. CONCLUSION Baseline and dynamic changes in Hb are associated with first-line treatment outcomes in patients with mRCC and may therefore represent a pragmatic early serological marker. Micro abstract In this retrospective cohort study of 276 patients with metastatic renal cell carcinoma (mRCC), we demonstrate that higher haemoglobin (Hb) levels prior to, and increases in Hb during systemic therapy predict better outcomes across three established frontline treatments. This study identifies Hb as a promising clinical marker of treatment outcomes in mRCC, of which there have been few to date.
oncology,urology & nephrology